Rebecca Kivlin
Optometrist · Fairfax, VANPI 1811369044
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $783, 4.1 times the $191 reported in 2019.
Across 92 payments — averaging $28.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$434
- Oyster Point Pharma, Inc.$421
- Bausch & Lomb Americas Inc.$347
- AbbVie$262
- Alcon$233
- Sun Pharmaceutical Industries Inc.$163
- plus $763 from 16 others
What the payments were for
- Food & beverage$2,624100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 25 | $434 |
| Oyster Point Pharma, Inc. | 17 | $421 |
| Bausch & Lomb Americas Inc. | 9 | $347 |
| AbbVie(2 entities) | 4 | $262 |
| Alcon | 5 | $233 |
| Sun Pharmaceutical Industries Inc. | 7 | $163 |
| Regeneron Healthcare Solutions, Inc. | 1 | $119 |
| Kedrion Biopharma, Inc. | 1 | $104 |
| Kala Pharmaceuticals, Inc. | 4 | $84 |
| Tarsus Pharmaceuticals, Inc. | 3 | $71 |
| Dompe US, Inc. | 3 | $60 |
| Sanofi | 1 | $48 |
| Johnson & Johnson Vision Care, Inc. | 2 | $44 |
| Novartis | 2 | $43 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $37 |
| Astellas Pharma US Inc | 1 | $36 |
| Harrow Eye, LLC | 1 | $23 |
| GSK | 1 | $22 |
| Coopervision Inc. | 1 | $20 |
| Thea Pharma Inc. | 1 | $20 |
| Omeros Corporation | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,624 in reported general payments places this provider in the 75th percentile of 1,230 optometrist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 67 | $101,672 |
| RestasisCyclosporine | 38 | $54,053 |
| LumiganBimatoprost | 60 | $31,505 |
| MieboPerfluorohexyloctane/Pf | 28 | $22,172 |
| TyrvayaVarenicline Tartrate | 15 | $12,120 |
| Cyclosporine | 17 | $6,583 |
| Latanoprost | 190 | $1,607 |
| Fluorometholone | 21 | $1,433 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 93 | $1,108 |
| ValacyclovirValacyclovir Hcl | 12 | $849 |
| ErythromycinErythromycin Base | 65 | $689 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 13 | $552 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 30 | $547 |
| Prednisolone Acetate | 12 | $438 |
| Ofloxacin | 17 | $207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $347 | $123,84495 claims |
| AbbVieRestasis, Lumigan | $262 | $85,55898 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $421 | $12,12015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,230 optometrist providers in Virginia.
Other optometrist in Fairfax
- James MatternFairfax$7K
- Walter WhitleyNorfolk$546K
- Jacqueline TheisRichmond$80K
- Joseph AllenRichmond$75K
- Keith SmithsonReston$74K
- Michael SwattsChesapeake$59K
- Kurt DevitoVirginia Beach$54K
- Walter SchlabachHarrisonburg$31K
- Mark AbrahamFalls Church$30K
- David TangVirginia Beach$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.